Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aligos Therapeutics Inc (ALGS)

Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,736
  • Shares Outstanding, K 6,154
  • Annual Sales, $ 3,950 K
  • Annual Income, $ -131,210 K
  • EBIT $ -87 M
  • EBITDA $ -86 M
  • 60-Month Beta 2.74
  • Price/Sales 15.52
  • Price/Cash Flow N/A
  • Price/Book 0.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.09
  • Number of Estimates 2
  • High Estimate -1.84
  • Low Estimate -2.34
  • Prior Year -3.41
  • Growth Rate Est. (year over year) +38.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.10 +15.60%
on 12/02/25
13.69 -23.15%
on 12/15/25
+1.01 (+10.56%)
since 11/24/25
3-Month
5.81 +81.07%
on 11/14/25
13.69 -23.15%
on 12/15/25
-0.23 (-2.14%)
since 09/24/25
52-Week
3.76 +179.79%
on 04/11/25
46.80 -77.52%
on 01/06/25
-28.82 (-73.26%)
since 12/24/24

Most Recent Stories

More News
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient...

ALGS : 10.52 (+5.73%)
Aligos Therapeutics Presents Positive Data at HEP-DART 2025

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class...

ALGS : 10.52 (+5.73%)
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient...

ALGS : 10.52 (+5.73%)
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class...

ALGS : 10.52 (+5.73%)
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through...

ALGS : 10.52 (+5.73%)
Aligos Therapeutics to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class...

ALGS : 10.52 (+5.73%)
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class...

ALGS : 10.52 (+5.73%)
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient...

ALGS : 10.52 (+5.73%)
H.C. Wainwright Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Aligos Therapeutics, with a price target of $50.00. The company’s shares opened today at $9.18.Elevate Your...

ALGS : 10.52 (+5.73%)
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class...

ALGS : 10.52 (+5.73%)

Business Summary

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 11.75
2nd Resistance Point 11.22
1st Resistance Point 10.87
Last Price 10.52
1st Support Level 9.99
2nd Support Level 9.46
3rd Support Level 9.11

See More

52-Week High 46.80
Fibonacci 61.8% 30.36
Fibonacci 50% 25.28
Fibonacci 38.2% 20.20
Last Price 10.52
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar